Danqing Kong

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Topics

Ulcerative Colitis

Newly Diagnosed

Aortic Dissection

Multiple Myeloma

Top Venues

British journal of haematology

Leukemia & lymphoma

Hematological oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jie Yin, Hong Tian, Danqing Kong, Yun Li, Chengyuan Gu, Zhaoyue Wang, Depei Wu, Ziqiang Yu
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment. British journal of haematology 199 (4) (2022)
Changju Qu, Nana Ping, Danqing Kong, Aining Liu, Hailing Liu, Ting Xu, Fan Xia, Depei Wu, Zhengming Jin
Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy. Hematological oncology (2022)
Danqing Kong, Yun Li, Chengcheng Fu, Mengjia Hou, Lingzhi Yan, Jingjing Shang, Zhaoyue Wang, Jie Yin, Ziqiang Yu, Depei Wu
Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Leukemia & lymphoma (2021)
Danqing Kong, Changju Qu, Hai-Ping Dai, Zheng Li, Jia Yin, Suning Chen, Liqing Kang, Guanghua Chen, Mingqing Zhu, Lei Yu, Depei Wu, Xiaowen Tang
CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph+ mixed phenotype acute leukaemia with minimal residual disease. British journal of haematology 191 (2) (2020)